-+ 0.00%
-+ 0.00%
-+ 0.00%

Cosmos Health expects Liv18 to generate over $5 million annual revenue

PUBT·04/20/2026 14:55:37
Listen to the news
Cosmos Health expects Liv18 to generate over $5 million annual revenue
  • Cosmos Health forecast Liv18 to generate more than $5 million in annual revenue with gross margin around 75% as it expands in US.
  • Production set to start in April 2026 at US GMP-certified, FDA-registered, UL-audited facilities, supporting localized supply chain.
  • Phase 1 execution completed ahead of schedule, covering product development, packaging, initial commercial setup.
  • Outlook reflects planned spending on advertising, customer acquisition, business development, supported by early US commercial traction across existing products.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202604201055ACCESSWRNAPR_____1158990) on April 20, 2026, and is solely responsible for the information contained therein.